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Background: Pulmonary alveolar proteinosis (PAP) is very rare in children. Only a few small series have been
published, with little information about long-term progression. The objective of our study was to describe the
clinical, radiological and pathological features, and the long-term course of PAP in a cohort of 34 children from
La Réunion Island.
Methods: Data were retrospectively collected from medical files. Radiological and pathological elements were
reviewed by two pediatric radiologists and three pathologists, respectively.
Results: Thirteen cases were familial and 32/34 (94%) cases were family connected. Disease onset occurred in
the first six months of life in 82% of the patients. Thoracic computed tomography scans showed the typical
“crazy-paving” pattern in 94% of cases. Respiratory disease was associated with a liver disorder, with the
detection of liver enlargement at diagnosis in 56% of cases. The course of the disease was characterized by
frequent progression to chronic respiratory insufficiency, accompanied by the appearance of cholesterol
granulomas and pulmonary fibrosis. Overall prognosis was poor, with a mortality of 59% and an overall five-year
survival rate from birth of 64%. Whole-lung lavages were performed in 21 patients, with no significant effect on
survival. Liver disease progressed to cirrhosis in 18% of children, with no severe complication.
Conclusions: PAP in children from la Réunion Island is characterized by an early onset, associated liver
involvement, poor prognosis and frequent progression to lung fibrosis, despite whole-lung lavages treatment.
The geographic clustering of patients and the detection of many familial links between most of the cases
strongly suggest a genetic etiology, with an autosomal recessive mode of inheritance.
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Pulmonary alveolar proteinosis (PAP) is a rare syndrome
characterized by the alveolar accumulation of lipopro-
teinaceous material [1]. Diagnosis is suggested on com-
puted tomography (CT) scans, showing a typical “crazy
paving” appearance and alveolar consolidations [2]. It
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unless otherwise stated.bronchoalveolar lavage fluid (BALF) or histological exami-
nations of lung biopsy specimens [3]. Most of the reported
cases occur in adults and are related to the presence of
anti-granulocyte macrophage colony stimulating factor
(GM-CSF) autoantibodies [4-6]. PAP is very rare in
children, with only a few small series and case reports
published to date. It may be primary or secondary to
various diseases, including immune deficiencies, meta-
bolic disorders and infections [7]. The mechanisms
underlying primary PAP in children remain unknown,
except for 15 published cases, for which mutations
were found in the genes encoding the alpha and beta
chains of the GM-CSF receptor [8-13]. The long-termLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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largely unknown. Whole-lung lavages (WLL) have been
reported to provide short-term benefits in both adults [5]
and children [10,14]. However, the long-term benefits of
such treatment are unknown for children. The aim of
this study was to describe the clinical, radiological and
pathological features and the long-term course of PAP
in a cohort of 34 patients from La Réunion Island.
Methods
Study design
We retrospectively reviewed the files of 34 children born
between 1970 and 2012, seen at La Réunion Island
University Hospital, with a diagnosis of PAP of unknown
cause, confirmed by pathological analysis. Eighteen of
these cases have been published before in other series but
with only a brief description [7,14-21]. In order to search
for known causes of PAP, immunological explorations
allowed to exclude immune deficiencies in all patients.
Chromatography of amino and organic acids in plasma
and urine were also performed in all patients and their
results excluded the diagnosis of lysinuric protein in-
tolerance in all of them. GM-CSF autoantibody assays
on serum and BALF were performed in 13 patients.
Sequencing of SFPTB, SFTPC, ABCA3, CSF2RA and
CSF2RB genes was performed for 17, 16, 10, 10 and 10
children, respectively. Two patients were heterozygous
for the missense variant p.Arg167Gln of the SFTPC gene.
This variant is reported as a single nucleotide polymorph-
ism (SNP) in computer databases (dbSNP reference:
rs34957318), its minor allele frequency was estimated at
9% among Réunion Island population [18] and this SNP
was also found in healthy individuals without any respira-
tory disorder [18]. The results of genes sequencing were
normal in the other patients. Radiological and pathological
data were reviewed by two pediatric radiologists and three
pathologists, respectively. This study was approved by
the Institutional Review Board of the French Respira-
tory Society (CEPRO 2013–019).
Genealogical studies
Family trees of patients were constructed by questioning
parents on their family history at diagnosis assessment
and retrieved form medical files. Furthermore, for the
purpose of this retrospective study, and when parental
consent was obtained, we reconstructed the thorough
ascending genealogy of patients, retracing their ancestry,
generation by generation, back in time. We identified
the ancestors of the patients from published genealogies
for Reunion Island for the years before 1935 [22,23],
or directly from the civil registration records for sub-
sequent years. These genealogies were stored in a com-
puter database comprising 6,105 individuals. We developed
a computer program to extract all genealogical pathslinking at least two patients and to identify couples of
common ancestors. We used Graphviz software [24]
to visualize the resulting genealogical network as a
marriage node graph [25] in which each couple is
represented by a single symbol (octagon) rather than
by two distinct individuals.
Data collection
The clinical data included sex, age and type of first
symptoms; age, clinical and biological features at diag-
nosis; mode of diagnosis; disease course and patient
outcome. A history of failure to thrive and/or progres-
sive dyspnea, sometimes associated with cough, vomiting
or digital clubbing, were considered as first symptoms
[26]. The radiologic lesions were classified according to
the Fleischner Society’s Glossary of Terms for Thoracic
Imaging [27]. The pathological review assessed the follow-
ing lesions: PAP, cholesterol clefts, pulmonary interstitial
and intra-alveolar cholesterol granulomas (PICG), other
inflammatory lesions and fibrosis. A semi-quantitative
grading scale was used to score each lesion, with 0 indi-
cating absence; + indicating rare or mild lesions; ++ indi-
cating moderate or localized lesions and +++ indicating
diffuse lesions.
Statistical analysis
Quantitative variables are presented as medians and inter-
quartile ranges (IQR). Qualitative variables are expressed
as percentages. Data were analyzed with Statview software
(Abacus Concepts Inc, Piscataway, New Jersey), by analysis
of variance, Fisher’s exact test, simple regression and
logistic regression. Survival analyses were performed by the
Kaplan-Meier method and group comparisons by logrank
tests. P < 0.05 was considered statistically significant.
Results
Genealogical studies
A primary analysis of families showed that 13 cases were
familial and clustered in five families (Figure 1). Consent
was obtained for thorough genealogical study for 25/27
families representing 32/34 patients (94% of our cohort).
All of these patients share couples of common ancestors
(Figure 2A and 2B). The most recent couple of common
ancestors married in 1731. Going back further in time
we found 32 couples of common ancestors to all studied
patients, who are thus potential carriers of a genetic
factor responsible for the disease (Figure 2B).
Lung pathology findings at diagnosis
The diagnosis was confirmed by BALF analysis in 15
patients, by the examination of lung specimens in 18
patients, and by both methods in one patient.
The 16 diagnostic BAL were performed at a median
age of 4.3 months (IQR: 3.4 – 13.7). In all reports, a
N 2 N 3 N 16 N 18 N 34N 31
1. 3.2.
N 10
N 12 N 23 N 32
N 7 N 6 N 9
5.4.
Figure 1 Genealogical trees of familial cases of pulmonary alveolar proteinosis from La Réunion Island. Genealogical trees of the 5
families with several cases of PAP. Familial forms of PAP in La Réunion Island in our study were characterized by the existence of at least one pair
of affected siblings per family in addition of one or two cousins for pedigrees 4 and 5. The coexistence of affected and unaffected children
among siblings, the fact that both sexes can be affected, the ascertained consanguinity in family 4 and the transversal distribution of the disease
are highly suggestive of an autosomic recessive mode of inheritance.
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analysis revealed the characteristic features of PAP, with
large foamy macrophages engorged with PAS–positive
inclusions and extracellular granular eosinophilic material,
equally PAS-positive. Details on BAL cell counts and
differentials are given in Table 1.
Examinations of lung specimens (n = 19) showed the
presence of PAP lesions in variable amounts (Table 2). PAP
lesions were isolated in five children (median age at lung
sampling: 6.1 months, 5 – 11.8) (Figure 3A). PICG lesions
were observed in eight patients, together with lesions of
PAP and pulmonary fibrosis. These eight patients were the
oldest at diagnosis (11.6 years, 8.3 – 15.4), and the greater
abundance of PICG lesions than of PAP lesions even led to
an initial diagnosis of cholesterol pneumonia in seven of
them. In the other six children (7.1 months, 3.8 – 30), PAP
lesions were observed together with small or moderate
numbers of cholesterol clefts, without granuloma. One of
these patients was also initially diagnosed with cholesterol
pneumonia. Inflammatory aspects, including septal thick-
ening and lymphocyte infiltrates, were present in 16 chil-
dren, with no particular distribution according to age.
General characteristics and medical history
Twenty-two patients were boys (sex ratio = 1.8). Nine pa-
tients (26%) were born preterm and 25 (74%) presented
intrauterine growth retardation, which was unexplained in
19 cases.Presentation at diagnosis: respiratory
Median age at diagnosis was 8.9 months (4–38.3). Age at
diagnosis was significantly lower in boys (5 months (3.8 -
28.1) versus 19.4 months (6–148.2) in girls, p = 0.014).
Respiratory symptoms and signs are described in Table 3.
The interval between the onset of symptoms and diagnosis
was variable, but early symptoms were observed in all but
two children, with a median age at the onset of symptoms
of 2.8 months (2 – 5). Twenty-eight patients (82%) pre-
sented with suggestive first symptoms within the first
six months of life, with a severity that led to a rapid
hospitalization for all of them. Four patients presented
with first symptoms between the ages of seven and
15 months, whereas symptoms were not noted until
the age of six years in the two remaining patients. Main
features for each patient are described in the online
Additional file 1: Table S1.
All patients had a chest X-ray during the diagnostic as-
sessment. It showed an appearance of alveolo-interstitial
or reticulo-nodular pattern in 31 patients and of “white
lungs” in the other three patients. Thoracic CT scans
taken at diagnosis or within the following year were
available for 17 patients. The lesions observed are de-
scribed in Table 4. Diffuse, symmetric involvement was
typically observed, with a characteristic “crazy-paving”
pattern in 94% of cases (Figure 4A). Consolidations were
observed in 76% of cases, predominantly with a postero-
basal location (Figure 4C). One patient with a very late
Figure 2 Genealogical analysis of cases of pulmonary alveolar proteinosis from La Réunion Island. A. Genealogical network connecting
the 32 patients for which a parental consent was obtained to their most recent couple of common ancestors. Each patient (squares for
boys and circles for girls) is denoted by his/her identifier. Each couple of ancestors is represented by an octagon of varying size and color
according to the number of patients for which they are ancestors (from 1 to 32 as illustrated by the inner scale). The most recent couple of
common ancestors (black octagon) married in 1731. Therefore, we can assert that all studied cases for which a consent was obtained are
family connected. B. Deepest analysis connecting the 32 patients for which a parental consent was obtained to all their common ancestors.
We found 32 couples of ancestors common to all patients (black octagons), each of them being a potential carrier of a genetic factor
reponsible of the disease.
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the age of 22 years) already had lesions suggestive of
fibrosis at diagnosis, with traction bronchiectasis and
honeycombing.Presentation at diagnosis: extra-respiratory
Extra-respiratory characteristics are detailed in Table 3.
Failure to thrive was frequent and weight was equal to
or below −4 standard deviations in 15 children. Liver
Table 1 Bronchoalveolar lavage cell counts and
differentials at diagnosis
Median IQR
Total cell count (ml−1)* 620,000 330,000 – 900,000
Differential (%)
Macrophages 62.5 48 – 75
Neutrophils 27.5 21.5 – 55
Lymphocytes 5 4.5 – 13
Data are presented as median and interquartiles range (IQR) for the 16
diagnostic broncho-alveolar lavages.
*Total cell count is reported for 8 BAL as BALF cellularity was undetermined
(described as “uncountable”) for the 8 others.




























Definition of abbreviations: IQR = interquartile range; OLB = open lung biopsy; TBB = tr
interstitial cholesterol granulomas. Data are presented at diagnosis and for the last ava
each lesion, with 0 indicating absence; + indicating rare or mild lesions; ++ indicating m
lesions were either isolated or associated with variable amounts of cholesterol clefts, ch
the 8 oldest cases of the series. At follow-up, although PAP lesions remained present b
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liver noted in 19 of the 34 patients (56%). Abnormal
liver test results were observed in 24 patients (71%). A
liver ultrasound scan was carried out at diagnosis or
within one year of diagnosis in 19 children and was abnor-
mal in 17 cases (89%), with the liver found to be enlarged
and containing a uniformly hyperechoic parenchyma sug-
gestive of steatosis.
The importance of chronic inflammation was highlighted
by high levels of immunoglobulin G and lactate de-
hydrogenase (LDH), thrombocytosis, hyperleukocytosis
and anemia. Malnutrition with hypoalbuminemia was
observed in 17 out of 25 patients (Table 3). No other
organ involvement suggestive of a multisystem disease
was detected.gical diagnosis specimen
(n = 19/34)
Last available histological
specimen (n = 14/34)
30 months 7.3 years
months −10.3 years) (6 years – 13.9 years)
16 (84) 1 (7)
1 (5) 9 (65)
2 (11) 2 (14)
0 (0) 2 (14)
19 (100) 13 (93)
7 (37) 6 (43)
3 (16) 5 (35)
9 (47) 2 (14)
8 (42) 8 (57)
0 (0) 1 (13)
2 (25) 5 (62)
6 (75) 2 (25)
14 (73) 14 (100)
5 (36) 5 (36)
3 (21) 4 (28)
6 (43) 5 (36)
8 (42) 10 (71)
1 (13) 1 (10)
2 (25) 3 (30)
5 (62) 6 (60)
16 (84) 13 (93)
9 (56) 9 (69)
4 (25) 3 (23)
3 (19) 1 (8)
ansbronchial biopsy; PAP = pulmonary alveolar proteinosis; PICG = pulmonary
ilable histological specimen. A semi-quantitative grading scale was used to score
oderate or localized lesions and +++ indicating diffuse lesions. At diagnosis, PAP
olesterol granulomas and fibrosis. Fibrosis was already observed at diagnosis in
ut in a lesser extent, PICG and fibrosis lesions were more frequent.
Figure 3 Pathological features. A: Lung histological specimen from a 9 months old boy, post-mortem examination. Diffuse intra alveolar
accumulation of granular eosinophilic proteinaceous material with rare cholesterol clefts and normal interalveolar septa typical of PAP. There was
no inflammation and no fibrosis. HES (×100). B: Lung histological specimen from a 9 years old girl, OLB. Numerous intra-alveolar cholesterol clefts
with giant cells associated with inflammatory cells and fibrosis, typical of PICG. Lesions predominantly observed in the subpleural part of the lung
parenchyma. Fatty involution of the visceral pleura (*). Tiny foci of PAP were also observed. HES (×100). C: Lung histological specimen from a 25 years
old woman, post-mortem examination. Lung sample displayed both PAP on the upper part of the figure (*) and PICG with cholesterol clefts, giant cells
granuloma, interstitial fibrosis and inflammation in the lower part of the figure. HES (×200). D: Liver histological specimen from a 2 years and 9 months
old boy. Micro nodular cirrhosis, steatosis, ductular proliferation without active inflammation. HES (×100).
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Overall mortality and survival analyses
Twenty patients (59%) died: five before the age of one
year, five between the ages of one and two years, two
later in childhood, four during adolescence and four during
adulthood (Figure 5). Two major groups of patients can be
identified (Figure 5): a group of patients dying early, within
the first two years of life (infancy), in a context of rapidly
progressive respiratory insufficiency (n = 10), and a group
of children that survived infancy (n = 19) with subsequent
progression, at various rates, to chronic respiratory symp-
toms, 9 of whom died. Besides, 4 patients are alive and
asymptomatic at follow-up (ages: 5.3, 8.5, 16.5 and
33.7 years). One patient died suddenly after an unex-
plained malaise. The overall five-year survival rate from
birth was 65% (Figure 6A). Age at death was significantly
lower in boys (16.9 months (6.9 months – 14.2 years))
than in girls (22.8 years (1.6 – 26.2), p = 0.011)) and five-
year survival from birth was also significantly lower in
boys than in girls (54% versus 83%, p = 0.04; Figure 6B).
Progression to chronic respiratory insufficiency (CRI) and
lung fibrosis
Nine patients died in a context of terminal CRI (Figure 5).
Among these patients, two died from postoperative com-
plications shortly after lung transplantation. Ten patientsare still alive but have respiratory problems (median age:
12.5 years, 11 – 19.6): one of these patients requires con-
tinuous oxygen supplementation, four require nocturnal
oxygen supplementation, four display exercise desaturation
only and one underwent lung transplantation one year ago
for terminal CRI. Since the lung transplantation, PAP did
not recur in this patient. Indeed, she had several BAL and
transbronchial lung biopsies after the transplantation and
there was no sign of pulmonary alveolar proteinosis nor on
BAL fluid neither on lung specimens’ examination.
Regarding lung function tests, lung volumes were nor-
mal in two patients. All the other patients in whom lung
function tests were carried out displayed a restrictive
pattern, with a median total lung capacity and median
vital capacity equal to 47% (37% – 59%) (n = 10) and
42% (31% – 53%) (n = 15) of the predicted values,
respectively. DLCO values were below 80% of the pre-
dicted value in 15 of 18 patients.
Thoracic CT scans were available for review for 13
patients (Table 4). All images showed persistent thickening
of the interlobular septa, intralobular lines and fissures
(Figure 4B and D). In 12 of 13 patients, the course of
the disease was characterized by the regression of
consolidation and distention zones, associated with the
appearance of lesions suggestive of fibrosis (Table 4, and
Figure 4B and D) [27].
Table 3 Clinical and biological features at diagnosis
n/total (%)*
Clinical characteristics
Dyspnea and/or tachypnea 34/34 (100)
Cough 9/34 (26)
Low SaO2 (<92%) or low PaO2 (<70 mmHg) 17/34 (50)
Crackles at pulmonary auscultation† 15/34 (44)
Digital clubbing 13/34 (38)






Anemia (Hb < 11 g/dL) 20/32 (63)
Hyperleukocytosis (≥15 000/mm3) 17/34 (50)
Thrombocytosis (≥450 000/mm3) 17/30 (57)
High IgG level 29/32 (90)
Hypoalbuminemia (<30 g/L) 17/25 (68)
Elevated AST 18/31 (58)
Elevated ALT 10/30 (33)
Elevated GGT 16/25 (64)
Elevated LDH 21/23 (91)
*: For some parameters, data were not available for all patients. †: For the 19
others patients, auscultation was reported as normal.
Table 4 Radiological features
Diagnosis CT Last available CT
n = 17 n = 13
Age (median (IQR)) 10 m (4.5 m – 22 y) 10 y (4.1 y – 14.1 y)
Elementary lesions n (%)
Ground glass opacity 16 (94) 13 (100)
Consolidation 13 (76) 1 (8)
Interlobular septal thickening 17 (100) 13 (100)
Intralobular lines 17 (100) 13 (100)
Distension 13 (76) 1 (8)
Fissures thickening 16 (94) 13 (100)
Micronodules 1 (6) 0 (0)
Cystic lesions 1 (6) 12 (92)
Traction bronchiectasis 1 (6) 11 (85)
Honeycombing 1 (6) 5 (40)
Data are presented at diagnosis and for the last available CT scan. Observed
lesions are reported according to the Fleischner Society’s Glossary of Terms for
Thoracic Imaging (32). At diagnosis, ground glass opacities, interlobular
thickening, intralobular lines and consolidations are the proeminent features.
At last follow-up, consolidations have disappeared and fibrotic lesions are
almost constant.
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gressive regression of PAP lesions accompanied by the
appearance of cholesterol granulomas and fibrosis
(Figure 3B, 3C and Table 2). At least one lung biopsy
was carried out in 28 patients. Lung fibrosis lesions
were identified on histological examination in 19 cases
(69%). Kaplan-Meier analysis based on the occurrence
of significant fibrosis (i.e. moderate or diffuse, n = 15
specimens) showed the probability of significant pul-
monary fibrosis to be almost 50% by the age of 14 years
(Figure 5C).Disease course according to treatment group and the
effects of WLL
Disease course according to treatment group is detailed
in Figure 5. WLL were not performed in 13 patients for
several reasons. Eight of these patients were the cases
initially diagnosed with cholesterol pneumonia. All pro-
gressed to CRI and seven of them died. The other five
cases were diagnosed before one year of age. Three died
from respiratory insufficiency within the first year of life.
PAP diagnosis in these cases was retrospective and based
on post-mortem lung sample analysis. The other two
patients were diagnosed before the introduction of WLL
for children. Both are still alive and have reached adult-
hood. One has exercise dyspnea and the other is
asymptomatic.
Overall, 67% (14/21) of the patients undergoing WLL
and 77% (10/13) of those not undergoing this treatment
survived infancy but this difference is not statistically
significant (p = 0.7). Similarly, WLL seemed to have no
influence on long-term prognosis. Progression to CRI
and/or death occurred whether or not patients under-
went WLL and this treatment had no significant effect
on survival rates (Figure 6D, p = 0.46). However, it is dif-
ficult to determine the true effect of WLL due to the
retrospective nature of this study and the heterogeneity
of the treated and non-treated groups, particularly in
terms of age at diagnosis. Even when we restricted the
analysis to patients diagnosed before the age of one year
with a larger number of WLL carried out earlier (WLL+,
n = 14/WLL-, n = 5), WLL had no significant effect on
overall survival rates (Figure 6E, p = 0.39).Other treatments
When lung fibrosis occurred or when lung biopsies
showed an important inflammation especially with lymph-
oid septal infiltrates, steroids were used either orally for
the first reported cases or IV with high dose regimen
from 1998. Other immunosuppressive treatments such
as hydroxychloroquine, azathioprine or cyclophospha-
mide have been used occasionally. Details on medica-
tions and treatments are given in Table 5.
Figure 4 Radiological features. A and B: CT scan from a girl at the ages of 9 (A) and 13 (B) years old. A: Typical aspect of crazy paving pattern
on thin axial sections: extensive areas of ground glass opacities (asterisks) superimposed with interlobular septa thickening (black arrows) and
intralobular lines (black arrowheads). Irregular thickening of fissures are also noted (white arrows). B: Ground glass opacities, interlobular septa
thickening and intralobular lines are less extensive than on the first CT scan while cystic lesions of a few millimetres (white arrowheads) are
observed, with a subpleural distribution. Irregular traction bronchiectasis (white arrows) appeared that are initial signs of pulmonary fibrosis. C and
D: CT scan of a girl at the ages of 8 months (C) and 5 years old (D). C: This CT scan image shows a symmetric combination of extensive ground-glass
opacities (asterisks), intralobular lines (arrowheads) and interlobular septa thickening (black arrows), associated to consolidation (black curved
arrows) in posterior areas of the lungs. Note the airspace hyperinflation in the anterior compartment of the lung (white asterisks) responsible of
an increasing density gradient from anterior to posterior areas. D: Extensive ground-glass opacities, intralobular lines and interlobular septa
thickening are still present. Subpleural cystic lesions (white arrowheads) and signs of fibrosis: honey-combing (white curved arrows) and traction
bronchiectasis (white arrows) appeared.
Figure 5 Treatment and outcome. Definition of abbreviations: WLL = whole lung lavages; ICU = intensive care unit; CRI = chronic respiratory
insufficiency, Tal CRI = terminal chronic respiratory insufficiency; LT = lung transplantation; Fp = pathologically documented lung fibrosis; Fr = lesions
suggestive of lung fibrosis on thoracic CT scan images; y = years. This figure consists in a flowchart of the study population according to treatment
group. For group of patients, ages are expressed as median.
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Figure 6 Survival and occurrence of fibrosis. All curves were performed using Kaplan-Meier method. A. Overall survival from birth showing a
5-year survival rate of 65%. B. Overall survival from birth according to gender. Five-year survival from birth was significantly lower in boys than in
girls (54% in boys versus 83% in girls, logrank test, p = 0.04). C. Occurrence of fibrosis according to the age at which lung biopsy was performed
showing a probability of significant pulmonary fibrosis of almost 50% by the age of 14 years old. D. Overall survival from birth with or without
WLL. WLL did not significantly change global survival rates (logrank test, p = 0.46). E. Overall survival from birth with or without WLL in patients
diagnosed before the age of one year with a larger number of WLL carried out earlier (WLL+, n = 14 / WLL-, n = 5). In this group, this treatment
did not significantly change global survival rates (logrank test, p = 0.39).
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Table 5 Treatments
Treatment Patients n (%)
WLL 21 (62)
Oral steroids 5 (15)





Mycophenolate mofetil 1 (3)
WLL, Whole lung lavages.
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A liver biopsy was performed in 12 children and two
specimens were obtained from autopsy. The results were
normal for 2 patients. However, one of these 2 patients
presented high levels of GGT and a hyperechoic liver on
ultrasound scan. Marked steatosis was observed in 9
cases. Fibrosis was observed in 10 patients and was clas-
sified as mild in 2 patients, extensive in 2 patients, and
as cirrhosis in 6 patients (Figure 3D). In all children with
extensive fibrosis or cirrhosis, regular screening was
carried out for liver failure and portal hypertension.
Grade I esophagal varices were found in five patients.
Screening for hepatopulmonary syndrome was negative
for all these patients. There were never signs of severe
liver failure.
Among the patients that did not have a liver biopsy,
18 cases presented with hepatomegaly or abnormal liver
tests results at some point in the course of the disease.
At last-follow-up or at death, 11 patients had a persist-
ent liver enlargement or abnormal liver tests results, 5
have normal liver tests results and no hepatomegaly and
for 2 there were no complete available data for liver
follow-up.
As a whole, 31 patients (91%) had a liver involvement
at some point in the course of the disease.
Failure to thrive and oral feeding difficulties required
initial parenteral nutrition in 10 patients (29%) and pro-
longed gastro-enteral feeding in 23 patients (67%).
Correlation of clinical and biological data with
pathological features
PICG lesions predominated in histological examinations
at diagnosis for some patients. We therefore carried out
additional analyses to determine whether the presence of
such lesions was associated with a specific pattern of
disease. The 28 patients that had had at least one lung
biopsy were divided into two groups according to the
presence of PICG lesions at some point in the course of
the disease (n = 13) or the absence of such lesions (n = 15).
We then assessed the association of these lesions with
age at biopsy and with the main features of the disease:age at first symptoms, liver involvement, WLL treat-
ment and outcome (dead or alive). Age at biopsy was
the only feature significantly associated with cholesterol
granulomas (mean age 10.8 years in the “PICG + ” group
versus 4 years in the “PICG -” group, p = 0.001). This
suggests that PICG lesions are part of the disease and
that these lesions appear during its progression.
Discussion
We report the largest series of cases of PAP in children
from La Réunion Island. This cohort had particular
characteristics: early onset, within the first months of
life, a severe course with frequent progression to pul-
monary fibrosis, associated liver involvement and more
severe disease in boys than in girls.
The early onset of the disease seems to be highly spe-
cific to our series. PAP is a very rare cause of chronic
lung disease in children, and is mostly diagnosed during
adulthood. A pediatric onset has been reported for the
forms due to CSF2RA and CSF2RB mutations, but at a
wide range of ages. For CSF2RA mutations, reported
ages at the onset of symptoms range from 1.5 to 9 years
[9]. For CSF2RB mutations, onset was neonatal in two
cases, occurred at the ages of one month and at nine
years in two other cases and during adulthood for the
last case [11-13].
The second characteristic feature of our series was the
severity of the disease, with a high rate of mortality and
frequent progression to pulmonary fibrosis. Published
mortality data relate to adult forms and report a better
prognosis, with a five-year survival rate from diagnosis
of 88% [5]. Moreover, in adult PAP, and for autoimmune
forms in particular, lung fibrosis is rarely described.
Several case reports have mentioned focal interstitial
fibrosis associated with adult PAP [28-32], but diffuse
fibrosis is actually a very rare occurrence, with only a few
cases reported [28,33-38]. In a cohort of 223 patients with
autoimmune PAP, lung fibrosis occurred in only two cases
(0.9%) [4]. In a retrospective radiologic study of 139
thoracic CT scans from 27 patients, substantial regions
of fibrosis were observed in only two patients (7%) [2].
In the adult with a CSF2RB mutation, thoracic CT scans
showed the progressive appearance of traction bronchi-
ectasis and cystic lesions suggestive of fibrosis [12], but
no lung fibrosis was described in children bearing
CSF2RA mutations [9,10].
Given the small size of our population and the retro-
spective nature of the study, it is difficult to evaluate
the efficacy of WLL in this cohort. Indeed, our clinical
experience and management of patients diagnosed in
the last 10 years suggest that WLL are effective in the
short term, whereas statistical analyses on the entire
cohort showed that there was no difference in survival
between treated and untreated children. There are
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First, the treated and untreated groups differed in
terms of age at diagnosis, clinical presentation and
severity. Second, this study covered a long time period
(42 years), during which substantial changes occurred
in both the WLL technique and the overall manage-
ment of these patients. Prospective data collection
would be required for the characterization of pheno-
typic groups and to identify the patients most likely to
benefit from WLL.
Liver disease was also a distinctive feature in these
patients, with no other organ involvement. As a whole,
31 patients (91%) had a liver involvement, and the ab-
sence of liver abnormalities in 3 patients could be attrib-
utable to a variable penetrance of this trait in this very
likely genetic syndrome. Hepatic involvement can be
observed in association with PAP in lysinuric protein
intolerance [39] and adenosine deaminase deficiency
[40,41], but has never been reported in other forms,
particularly those of the autoimmune type that is the
most reported type of PAP. In our cohort, it is debatable
whether the steatosis observed arose due to the severe
malnutrition often present at diagnosis. However, the
ultrasound findings were at all ages and in all states of
nutrition suggestive of fat overload in the liver. Liver
disease progressed to extensive fibrosis or cirrhosis in
seven children in the absence of severe complications of
portal hypertension or liver failure.
The pathophysiological mechanism underlying PAP in
these children remains unknown. The clustering of this
disease in a specific geographic area, the existence of
cases among closely related individuals and the results
of our thorough genealogical study (94% of patients are
family connected) strongly suggest a genetic origin.
Moreover, the frequency of inbreeding in this geographic
area during the 18th and 19th centuries [42], the absence
of vertical transmission (i.e. parent-to-child transmis-
sion) with all parents being healthy, and the recurrence
among siblings are highly suggestive of an autosomal re-
cessive mode of inheritance.
As the GM-CSF pathway has been implicated in the
autoimmune form and in known genetic forms, genes
encoding targets or partners of GM-CSF (reviewed in [3]
and [43]) are potentially good candidates. However, the
available animal models of disrupted GM-CSF signalling
[44,45] inducing a PAP phenotype have no liver pheno-
type and display no progression to pulmonary fibrosis.
Furthermore, a dysfunction of GM-CSF signalling would
led to alveolar macrophages’ dysfunction. In this hypoth-
esis, one could expect that the disease would recur in
transplanted patients. The absence of recurrence of the
disease in the alive patient who underwent lung trans-
plantation one year ago is one argument against the
pivotal role of macrophages in the pathophysiology ofthis disorder. Nevertheless, it is impossible to draw defini-
tive conclusions from the analysis of a single case with a
relatively short follow-up since lung transplantation.
The associated liver involvement observed in our series
raised questions about possible abnormal phospholipid
metabolism or transport in both type II alveolar epithelial
cells (type II AEC) and hepatocytes, potentially leading to
abnormal surfactant turnover and fat overload in the liver.
The fibrotic progression of the disease also suggests a
potential role of type II AEC in this disease. Patho-
logical review showed that inflammatory lesions were
present at diagnosis in 16 children, seven of whom were
investigated before the age of two years, suggesting that
the inflammatory and subsequent fibrotic processes
may occur at the same time as the accumulation of
abnormal lipoproteinaceous material, rather than after
this accumulation. PAP is classically characterized by
preservation of the architecture of the alveoli, with
normal and thin alveolar walls and rare descriptions of
lymphocytic infiltrates [3,5]. In interstitial lung diseases
caused by SFTPC mutations, mutant surfactant protein
C has been shown to accumulate in the endoplasmic
reticulum (ER), leading to ER stress, type II AEC injury,
inflammation and the activation of apoptosis [46,47].
All these mechanisms seem to be involved in the
fibrotic progression associated with SFTPC mutations
[48]. In the disease described here, similar mechanisms
could be suggested, with a genetic mutation leading to
an abnormal protein that is misfolded in the ER, lead-
ing to inflammation and fibrosis. The defective func-
tioning of this abnormal protein would also lead to
abnormal surfactant turnover and accumulation in the
alveoli. The important systemic inflammation in those
children could also play a role in the development of
lung fibrosis.
The reasons for the greater severity of disease in boys
remain to be determined, and will probably become
clearer when genetic analyses have determined the
etiology of the disease. X-linked inheritance is very
unlikely because both boys and girls can be affected by the
disease which exclude a recessive X-linked disorder. As
mentioned above, there is no case of parent-to-child trans-
mission and this element a priori excludes a dominant
X-linked mode of inheritance. Instead, modifier genes
or hormonal factors may be involved.
In conclusion, we describe a cluster of 34 cases of pri-
mary PAP in children from La Réunion Island with very
particular features, including a high rate of mortality and
frequent progression to cholesterol granulomas and
pulmonary fibrosis, despite WLL treatment. In this setting,
the cause is very likely to be genetic, with an autosomal
recessive mode of inheritance. Genetic studies should
make it possible to determine the cause and mechanism
of PAP and fibrosis in this population.
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